AgeX Therapeutics, Inc. (commonly abbreviated as AgeX Therapeutics or simply AgeX) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others.The company’s vice president of new technology discovery is Aubrey de Grey, who also serves as chief scientific officer of the SENS Research Foundation. The chairman is Gregory Bailey, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.In January 2020, AgeX Therapeutics announced a research collaboration with a Japanese biopharma company utilizing AgeX’s UniverCyte technology platform.
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 29.94M; Volume: 282.31K; AvgVol 3m: 425.20K; Beta: –;
P/E: –; EPS: -0.32; EPS growth quarter/prev quarter: 13.00%;
EPS growth this year: -51.80%; EPS growth past 5 years: ;
EPS ttm: -0.31;
P/S: 16.66; P/B: ; P/Cashflow: 31.66; P/FCF: ;
Sales: 1.89M; Sales growth quarter/prev quarter: 0.00%; Sales growth past 5 years: ;
Gross Margin: 89.50%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -185.40%; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.10%; Insider Transactions:0.00%;
Institutional Ownership: 21.10%; Institutional Transactions: -13.01%;
Data update: 07.10.2020.